Skip to main content
AMANTA · Health Care · 2026-08-07

Amanta Healthcare Ltd

4.6WatchEven +1.3Stage 2 · wk 5In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹166.2
-2.00% today
₹645 Cr · Small cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Amanta Healthcare Limited operates as a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products and parenteral products in Africa, Latin America, the United Kingdom, and internationally. The company manufactures its products in three product group segments Large Volume Parenteral, Nipple Head (Single Port), SteriPort (Two Ports), and Small Volume Parenteral. Additionally, it manufactures medical devices and fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products, such as irrigation, first-aid solution, and eye lubricants in medical device segment. It also offers a wide range of closure systems, such as nipple head, twist-off, leur-lock, and screw types and container fill-volume ranging from 2ml to 1000 ml. Its markets its products through three strategic business units including national sales, international sales, and product partnering with various foreign and Indian pharmaceutical companies. Amanta Healthcare Limited was formerly known as Marck Biosciences Limited and changed its name to Amanta Healthcare Limited in June 2014. Amanta Healthcare Limited was incorporated in 1994 and is headquartered in Ahmedabad, India.

Visit company website →
P/E (TTM)
30.4
Forward —
Earnings Growth (YoY)
-23.4%
Revenue +6.8%
ROE
+9.4%
Profit margin +5.2%
vs 52W High
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 5
1w13w26w
Week 5 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
33.4%
200 DMA: ₹124.5 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.01x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -1.2% vs MA50 +9.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2025-09-11 → 2026-08-07
S? 43w
S2 5w
2025-09-112026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S2 5w current
Total tracked: 47 weeks across 2 stage runs.
1M
-9.1%
3M
+19.7%
6M
+61.7%
YTD
+55.6%
1Y
Scan Membership
Prop Scan
Latest: 2026-08-07
Breakout Watch
Latest: 2026-07-07
25 appearances in last 60 days. First seen: 2026-07-07.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 5 · Vol x
2026-08-06S2
Wk 5 · Vol x
2026-08-05S2
Wk 5 · Vol x
2026-08-04S2
Wk 5 · Vol x
2026-08-03S2
Wk 4 · Vol x
2026-07-31S2
Wk 4 · Vol x
2026-07-30S2
Wk 4 · Vol x
2026-07-29S2
Wk 4 · Vol x
2026-07-28S2
Wk 4 · Vol x
2026-07-27S2
Wk 3 · Vol x
2026-07-24S2
Wk 3 · Vol x
2026-07-23S2
Wk 3 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹158.3
200 DMA
₹124.5
52W High
52W Low
5D Low
₹166.2
Resistance levels (recent highs)
20d High
₹175.6
60d High
₹186.5
120d High
₹186.5
250d High
Next resistance
+5.7%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.